Clinical Efficacy of Montelukast on Childhood Asthma,Changes of Lung Function and Cytokines

Objective To evaluate the clinical efficacy of montelukast on childhood asthma,and its relationship with lung function,NF-κB,IL-6 and IL-8. Methods A total of 82 8-14 years old patients with childhood asthma who were treated in Department of Pediatrics in Affiliated Hospital of Guangdong Medical College from July 2012 to July 2013,were divided into control group( 40 cases) and treatment group( 42 cases) by using random number table method. All case in both groups were given atomization inhalation of budesonide, relieving cough and reducing sputum treatment, atomization inhalation of βreceptor agonists during asthma exacerbation,and antibacterial drugs if infection existed; cases in treatment group were given montelukast sodium chewable tablets 5 mg / d for 12 weeks. The clinical efficacy was observed,lung function was detected,and ELISA was used to detect levels of NF-κB,IL-6 and IL-8. Results After treatment,no control 10 cases,part of control 10 cases,control 20 cases in control group; no control 4 cases,part of control 5 cases,control 33 cases in treatment group. There was significant difference in clinical efficacy between the two groups( u =-2. 680,P = 0. 007). Before treatment,there was no significant difference in FEV1,PEF,levels of NF-κB,IL-6 and IL-8 between the two groups of cases( P 0. 05).After treatment,FEV1 and PEF of cases in treatment group was significantly higher than those of cases in control group( P 0. 05),respectively,and the levels of NF-κB,IL-6 and IL-8 in treatment group were significantly lower than those in control group( P 0. 05). Conclusion Montelukast can significantly improve children's asthma symptoms and signs,improve lung function,and reduce levels of NF-κB,IL-6 and IL-8.